RespiratoryRegeneron
Regeneron Reports Phase 3 LIBERTY ASTHMA TRAVERSE Results for Dupixent in Asthma
BMI
Biotechnology Media Insights
Editorial Team · June 5, 2023
Regeneron and Sanofi announce Phase 3 LIBERTY ASTHMA TRAVERSE trial results showing Dupixent maintains asthma control over long-term treatment.
Regeneron and Sanofi today announced results from the Phase 3 LIBERTY ASTHMA TRAVERSE trial evaluating long-term treatment with Dupixent (dupilumab) in patients with moderate-to-severe asthma. The trial demonstrated that Dupixent maintained significant reductions in asthma exacerbation rates and improvements in lung function over 96 weeks of treatment.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.